Categories: HealthcareNewsVaccine

Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology

Research & Development Council of New Jersey honors Avantor for developing a biodegradable detergent solution that advances safe, sustainable biomanufacturing

RADNOR, Pa., Nov. 25, 2025 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the Company, in partnership with Amgen, received a 2025 Edison Patent Award from the Research & Development Council of New Jersey. The recognition was for their pioneering development of a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing.

Co-developed by Avantor and Amgen, Avantor’s detergent delivers effective viral inactivation while maintaining protein integrity and increasing process yield. This jointly developed technology addresses a critical industry challenge by providing a compliant, high-performing, and environmentally responsible alternative for producing monoclonal antibodies, vaccines, and gene therapies.

“We are honored to be recognized by the R&D Council of New Jersey for this achievement,” said Benoit Gourdier, Executive Vice President, Bioscience Production, Avantor. “Our collaboration demonstrates how strategic partnerships can drive scientific innovation and environmental responsibility to advance biomanufacturing. By developing safer, more effective detergents, Avantor is supporting our customers in producing vital therapies responsibly and with less impact on the environment.”

Co-developed at Avantor’s Bridgewater Innovation Center, this work strengthens Avantor’s leadership in sustainable bioprocessing while showcasing the power of industry collaboration. The partnership also reinforces New Jersey’s position as a global hub for scientific innovation and sustainable technology.

Read more about how Avantor developed J.T.Baker Viral Inactivation here.

About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedInX (Twitter) and Facebook.

Avantor Media Contact
Eric Van Zanten
Head of External Communications
610-529-6219
Eric.Vanzanten@avantorsciences.com 

Avantor Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
908-329-7281
Allison.Hosak@avantorsciences.com

View original content:https://www.prnewswire.com/news-releases/avantor-receives-2025-edison-patent-award-for-sustainable-viral-inactivation-technology-302624676.html

SOURCE Avantor and Financial News

Staff

Recent Posts

Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026

LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…

1 hour ago

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the…

10 hours ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope…

10 hours ago

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…

10 hours ago

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal…

10 hours ago